Get the Stockscreener App
7.73
0.90%
-0.07
Pre-market:
7.68
-0.05
-0.65%
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols Sa Adr stock is traded at $7.73, with a volume of 1.29M.
It is down -0.90% in the last 24 hours and up +7.51% over the past month.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
See More
Previous Close:
$7.80
Open:
$7.72
24h Volume:
1.29M
Relative Volume:
1.40
Market Cap:
$5.25B
Revenue:
$7.57B
Net Income/Loss:
$216.85M
P/E Ratio:
24.35
EPS:
0.3174
Net Cash Flow:
$709.16M
1W Performance:
-6.53%
1M Performance:
+7.51%
6M Performance:
-16.07%
1Y Performance:
+14.18%
1-Day Range:
$7.435
$7.84
1-Week Range:
$7.435
$8.81
52-Week Range:
$5.68
$9.96
Grifols Sa Adr Stock (GRFS) Company Profile
Name
Grifols Sa Adr
Sector
Industry
Phone
-
Address
-
Compare GRFS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.73 | 5.25B | 7.57B | 216.85M | 709.16M | 0.3174 |
|
LLY
Lilly Eli Co
|
824.06 | 783.19B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
213.59 | 377.06B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
78.11 | 346.73B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
165.86 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.73 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Resumed | Morgan Stanley | Overweight |
| Mar-12-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
| Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-20-21 | Initiated | Deutsche Bank | Hold |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
| Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
| Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
| Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
| Jun-01-18 | Initiated | Barclays | Overweight |
| Oct-31-17 | Initiated | Citigroup | Buy |
| Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-17 | Initiated | BofA/Merrill | Buy |
| Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
| Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols Sa Adr Stock (GRFS) Latest News
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Grifols SA ADR (GRFS) stock last session? - US Post News
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GRFS’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
How does Grifols SA ADR (GRFS) change from a tortoise to a hare? - SETE News
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
The Significance of Moving Averages in Grifols SA ADR Inc. (GRFS) Price Performance - The InvestChronicle
Have you been able to find a good deal on Grifols SA ADR’s shares? - US Post News
Closing Figures: Grifols SA ADR (GRFS)’s Negative Finish at 8.41, Down -1.87 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: Grifols SA ADR (GRFS) - SETE News
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
Grifols Class B stock discounted by Brookfield (NASDAQ:GRFS) - Seeking Alpha
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Grifols SA ADR (GRFS) looking to reclaim success with recent performance - SETE News
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Validea Joseph Piotroski Strategy Daily Upgrade Report8/6/2024 - Nasdaq
Grifols revises past financial records with equity value drop of $494 mln - Marketscreener.com
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols receives takeover interest from its founding family, Brookfield fund; to go private - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols shares fall after new Gotham City Research report - Marketscreener.com
Grifols Sa Adr Stock (GRFS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):